Opfolda (Miglustat) Patent Expiration, LOE Window & CMS Spending
Opfolda (Miglustat) by Amicus Therapeutics Us: FDA Orange Book core substance LOE 2035-09-30 (last listed 2038-09-16), 3 AB generics, $54K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amicus Therapeutics Us |
| FDA Application & Pathway | N215211 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-09-30 |
| Last Listed Patent or Exclusivity Date | 2038-09-16 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $54K |
| 2024 Medicare Part D Spend | $41K |
| 2024 Medicaid Spend | $14K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |